ASC-US Management Guidelines

Definition and Clinical Significance

The American College of Family Physicians notes that ASC-US represents approximately 4% of all cervical cytology smears and indicates cellular changes that are more pronounced than inflammatory or reactive processes but insufficient to be classified as cervical intraepithelial lesions (CIN) 1
The risk of underlying high-grade cervical disease (CIN 2 or worse) in non-adolescent women with ASC-US is approximately 9.7% 1
ASC-US is the most common abnormal Pap test result and serves as an important triage point in cervical cancer screening, according to the American College of Family Physicians 2, 3

The American College of Family Physicians recommends that the preferred management of ASC-US in adult women is reflex HPV DNA testing 2, 1
For HPV-positive ASC-US, the Centers for Disease Control and Prevention recommends colposcopy for immediate evaluation 4, 2
For HPV-negative ASC-US, the Centers for Disease Control and Prevention recommends repeat HPV test with or without concurrent Pap test in 3 years 4
The National Comprehensive Cancer Network notes that for women aged 21-24 years, management may differ due to high rates of HPV infection and spontaneous regression in this age group 5
For pregnant women, the American College of Family Physicians and the National Comprehensive Cancer Network recommend colposcopic biopsy of lesions suspicious for cancer or CIN 2/3 2, 5
For HIV-infected women, the Infectious Diseases Society of America recommends more aggressive follow-up as they have higher rates of progression to SIL (60% vs 25% in HIV-negative women) 6

The Centers for Disease Control and Prevention notes that HPV status is the most important risk stratifier for women with ASC-US 4, 1
The National Comprehensive Cancer Network reports that the 5-year risk of histologic HSIL and cancer for HPV-positive ASC-US is 18%, compared to only 1.1% for HPV-negative ASC-US 5
The Centers for Disease Control and Prevention recommends that previous abnormal cervical screening results be considered a risk factor for women with ASC-US 4

The American College of Family Physicians recommends that if colposcopy is negative, follow-up includes repeat cytology at 6 and 12 months, or HPV testing at 12 months, with colposcopic reevaluation if HPV testing is positive or cytology is ASC-US or greater 2, 1
The American Cancer Society notes that failure to follow up on ASC-US results is a common cause of delayed diagnosis of cervical cancer, and timely follow-up is essential - delays beyond 180 days are associated with increased risk of progression 7

The Centers for Disease Control and Prevention recommends repeat co-testing (Pap plus HPV) in 1 year for patients with ASC-US and negative HPV testing, as the HPV-negative status is the critical risk stratifier that determines management timing 8

The American College of Obstetricians and Gynecologists, as reflected in the 2021 CDC guidelines, recommends repeat co-testing (Pap + HPV) in 1 year for women with ASC-US and negative HPV testing 8
If both tests are negative at the 1-year follow-up, the patient should return to routine screening per age-appropriate guidelines, as indicated by the CDC 8
If HPV is positive or cytology shows ASC-US or greater at the 1-year follow-up, the patient should proceed to colposcopy, according to the CDC guidelines 8

The CDC guidelines note that prior cryotherapy history does not change the recommendation for repeat co-testing in 1 year unless there was a history of high-grade lesions, which would warrant colposcopy 8
The CDC guidelines also recommend against simply repeating cytology alone without HPV testing, as co-testing is preferred for follow-up after abnormal results 8
A history of previous high-grade cervical lesions would indicate immediate colposcopy instead of repeat co-testing, as per the CDC guidelines 8